CLDN7

Across TCGA pan-cancer cohorts, CLDN7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLDN7 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CLDN7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN7 expression acts as an unfavorable survival marker.

SKCM and LIHC are the cancer types where CLDN7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.072	0.877	<.001	36	view →
LIHC	DFS	Median	All	0.076	0.553	.002	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLDN7–SKCM (OS)

Open the SKCM breakdown →